News!!!!!! MRNA -- Marina Biotech - 500 Beiträge pro Seite
eröffnet am 08.07.11 16:13:53 von
neuester Beitrag 29.11.11 19:59:01 von
neuester Beitrag 29.11.11 19:59:01 von
Beiträge: 56
ID: 1.167.458
ID: 1.167.458
Aufrufe heute: 0
Gesamt: 2.906
Gesamt: 2.906
Aktive User: 0
ISIN: US00687E4061 · WKN: A3DWU1 · Symbol: ATRX
0,0075
USD
+11,79 %
+0,0008 USD
Letzter Kurs 02:10:00 Nasdaq OTC
Werte aus der Branche Biotechnologie
| Wertpapier | Kurs | Perf. % |
|---|---|---|
| 52,25 | +93,52 | |
| 1,9000 | +59,66 | |
| 0,6000 | +57,48 | |
| 2,2999 | +25,68 | |
| 1,9200 | +23,87 |
| Wertpapier | Kurs | Perf. % |
|---|---|---|
| 0,8500 | -12,97 | |
| 2,2900 | -17,63 | |
| 2,6700 | -28,03 | |
| 5,2300 | -32,95 | |
| 9,6900 | -33,06 |
Feedback
Marina Biotech Reports Significant Developments in Its Ability to Develop Both microRNA Mimetics and Antagonists
2011-07-08 08:30 ET - News Release
BOTHELL, WA -- (MARKET WIRE) -- 07/08/11
Marina Biotech, Inc. (NASDAQ: MRNA), a leading nucleic acid-based drug discovery and development company, reported data demonstrating that its proprietary technologies, its liposomal-based delivery technology SMARTICLES® as well as its Conformationally Restricted Nucleotide (CRN) technology, support the development of both microRNA (miRNA) mimetics and antagonists. Systemic administration of a SMARTICLES formulated miRNA mimetic in an orthotopic liver tumor model demonstrated inhibition of tumor growth, as indicated by a decrease in a systemic liver tumor biomarker, alpha-feto protein, and a decrease in tumor weight of greater than 80%. In separate work, the Company demonstrated that incorporation of CRN in miRNA antagonists increased potency with an approximate 60-fold improvement in the IC50. MicroRNAs have pivotal roles in cell biology, including diseases such as inflammation and cancer, and involve both over-expression and under-expression of specific miRNAs. Thus, effective intervention may involve a mimetic to replace an under-expressed miRNA or an antagonist to inhibit the activity of an over-expressed miRNA. The data were presented by Michael V. Templin, Ph.D., Senior Vice President, Preclinical Development at Marina Biotech, Inc., at the 2nd RNAi Research & Therapeutics Conference, July 7-8, 2011 in San Francisco, CA.
"We continue to demonstrate the breadth of our nucleic acid-based drug discovery engine," stated Dr. Templin. "Pharmaceutical companies are clearly interested in developing nucleic acid therapeutics to meet their 'undruggable target' needs. The ability to apply multiple oligonucleotide modalities in response to a particular undruggable target, therapeutic indication and patient phenotype is critical for an effective drug discovery engine since it provides pharma options upon which they can make decisions based on both the scientific and business risks associated with each nucleic acid-based approach. This recent data demonstrates our ability to create proprietary miRNA therapeutics; both mimetics and antagonists. We have now demonstrated the capability to develop a variety of double-stranded and single-stranded oligonucleotide compounds harnessing several biological pathways including RNA interference. This capability, provided through proprietary chemistry and delivery technologies, is unique to Marina Biotech and significantly sets us apart from others in this space."
About SMARTICLES®
SMARTICLES define a novel class of liposomes: fully charge-reversible particles for delivery of active substance (siRNA, antisense, decoy, etc.) inside the cell either by local or systemic administration. SMARTICLES are designed to ensure: (1) stable passage through the bloodstream and (2) release of the nucleic acid payload within the target cell to exert its therapeutic effect.
About Conformationally Restricted Nucleotides
Conformationally Restricted Nucleotides are analogs in which a chemical bridge connects the C2' and C4' carbons of ribose. Ribose, a five-carbon ring-like structure, forms the central region of a nucleotide (comprised of a nucleobase, ribose, and phosphate group). The chemical bridge in the ribose of a CRN locks the ribose in a fixed position, which in turn restricts the flexibility of the nucleobase and phosphate group. Substitution of a CRN within an RNA- or DNA-based oligonucleotide has the advantages of increased hybridization affinity and enhanced resistance to nuclease degradation. CRN technology provides a direct means of developing highly potent and specific nucleic acid-based therapeutics to target messenger RNAs or microRNAs. These targets represent disease pathways that are typically "undruggable" or "difficult to target" by small molecule or monoclonal antibodies, and are appropriate for disease areas with significant unmet needs, such as inflammation, metabolic disease, and cancers. The CRN patent estate consists of two issued patents broadly covering CRN compounds and CRN containing oligonucleotides, and one pending patent application covering additional applications of CRNs.
About Marina Biotech, Inc.
Marina Biotech is a biotechnology company, focused on the development and commercialization of RNA interference- (RNAi) and RNA-based therapeutics. The Marina Biotech pipeline currently includes a clinical program in Familial Adenomatous Polyposis (a precancerous syndrome) and two preclinical programs -- in bladder cancer and malignant ascites. Marina Biotech entered into an exclusive agreement with Debiopharm Group for the development and commercialization of the bladder cancer program. Marina Biotech's goal is to improve human health through the development of RNAi and RNA-based compounds and drug delivery technologies that together provide superior therapeutic options for patients. Additional information about Marina Biotech is available at http://www.marinabio.com.
Forward-Looking Statements
Statements made in this news release may be forward-looking statements within the meaning of Federal Securities laws that are subject to certain risks and uncertainties and involve factors that may cause actual results to differ materially from those projected or suggested. Factors that could cause actual results to differ materially from those in forward-looking statements include, but are not limited to: (i) the ability of Marina Biotech to obtain additional funding; (ii) the ability of Marina Biotech to attract and/or maintain manufacturing, research, development and commercialization partners; (iii) the ability of Marina Biotech and/or a partner to successfully complete product research and development, including preclinical and clinical studies and commercialization; (iv) the ability of Marina Biotech and/or a partner to obtain required governmental approvals; and (v) the ability of Marina Biotech and/or a partner to develop and commercialize products that can compete favorably with those of competitors. Additional factors that could cause actual results to differ materially from those projected or suggested in any forward-looking statements are contained in Marina Biotech's most recent periodic reports on Form 10-K and Form 10-Q that are filed with the Securities and Exchange Commission. Marina Biotech assumes no obligation to update and supplement forward-looking statements because of subsequent events.
Contact:
Marina Biotech, Inc.
Michael V. Templin, Ph.D.
Senior Vice President, Preclinical Development
(425) 908-3057
Email Contact
2011-07-08 08:30 ET - News Release
BOTHELL, WA -- (MARKET WIRE) -- 07/08/11
Marina Biotech, Inc. (NASDAQ: MRNA), a leading nucleic acid-based drug discovery and development company, reported data demonstrating that its proprietary technologies, its liposomal-based delivery technology SMARTICLES® as well as its Conformationally Restricted Nucleotide (CRN) technology, support the development of both microRNA (miRNA) mimetics and antagonists. Systemic administration of a SMARTICLES formulated miRNA mimetic in an orthotopic liver tumor model demonstrated inhibition of tumor growth, as indicated by a decrease in a systemic liver tumor biomarker, alpha-feto protein, and a decrease in tumor weight of greater than 80%. In separate work, the Company demonstrated that incorporation of CRN in miRNA antagonists increased potency with an approximate 60-fold improvement in the IC50. MicroRNAs have pivotal roles in cell biology, including diseases such as inflammation and cancer, and involve both over-expression and under-expression of specific miRNAs. Thus, effective intervention may involve a mimetic to replace an under-expressed miRNA or an antagonist to inhibit the activity of an over-expressed miRNA. The data were presented by Michael V. Templin, Ph.D., Senior Vice President, Preclinical Development at Marina Biotech, Inc., at the 2nd RNAi Research & Therapeutics Conference, July 7-8, 2011 in San Francisco, CA.
"We continue to demonstrate the breadth of our nucleic acid-based drug discovery engine," stated Dr. Templin. "Pharmaceutical companies are clearly interested in developing nucleic acid therapeutics to meet their 'undruggable target' needs. The ability to apply multiple oligonucleotide modalities in response to a particular undruggable target, therapeutic indication and patient phenotype is critical for an effective drug discovery engine since it provides pharma options upon which they can make decisions based on both the scientific and business risks associated with each nucleic acid-based approach. This recent data demonstrates our ability to create proprietary miRNA therapeutics; both mimetics and antagonists. We have now demonstrated the capability to develop a variety of double-stranded and single-stranded oligonucleotide compounds harnessing several biological pathways including RNA interference. This capability, provided through proprietary chemistry and delivery technologies, is unique to Marina Biotech and significantly sets us apart from others in this space."
About SMARTICLES®
SMARTICLES define a novel class of liposomes: fully charge-reversible particles for delivery of active substance (siRNA, antisense, decoy, etc.) inside the cell either by local or systemic administration. SMARTICLES are designed to ensure: (1) stable passage through the bloodstream and (2) release of the nucleic acid payload within the target cell to exert its therapeutic effect.
About Conformationally Restricted Nucleotides
Conformationally Restricted Nucleotides are analogs in which a chemical bridge connects the C2' and C4' carbons of ribose. Ribose, a five-carbon ring-like structure, forms the central region of a nucleotide (comprised of a nucleobase, ribose, and phosphate group). The chemical bridge in the ribose of a CRN locks the ribose in a fixed position, which in turn restricts the flexibility of the nucleobase and phosphate group. Substitution of a CRN within an RNA- or DNA-based oligonucleotide has the advantages of increased hybridization affinity and enhanced resistance to nuclease degradation. CRN technology provides a direct means of developing highly potent and specific nucleic acid-based therapeutics to target messenger RNAs or microRNAs. These targets represent disease pathways that are typically "undruggable" or "difficult to target" by small molecule or monoclonal antibodies, and are appropriate for disease areas with significant unmet needs, such as inflammation, metabolic disease, and cancers. The CRN patent estate consists of two issued patents broadly covering CRN compounds and CRN containing oligonucleotides, and one pending patent application covering additional applications of CRNs.
About Marina Biotech, Inc.
Marina Biotech is a biotechnology company, focused on the development and commercialization of RNA interference- (RNAi) and RNA-based therapeutics. The Marina Biotech pipeline currently includes a clinical program in Familial Adenomatous Polyposis (a precancerous syndrome) and two preclinical programs -- in bladder cancer and malignant ascites. Marina Biotech entered into an exclusive agreement with Debiopharm Group for the development and commercialization of the bladder cancer program. Marina Biotech's goal is to improve human health through the development of RNAi and RNA-based compounds and drug delivery technologies that together provide superior therapeutic options for patients. Additional information about Marina Biotech is available at http://www.marinabio.com.
Forward-Looking Statements
Statements made in this news release may be forward-looking statements within the meaning of Federal Securities laws that are subject to certain risks and uncertainties and involve factors that may cause actual results to differ materially from those projected or suggested. Factors that could cause actual results to differ materially from those in forward-looking statements include, but are not limited to: (i) the ability of Marina Biotech to obtain additional funding; (ii) the ability of Marina Biotech to attract and/or maintain manufacturing, research, development and commercialization partners; (iii) the ability of Marina Biotech and/or a partner to successfully complete product research and development, including preclinical and clinical studies and commercialization; (iv) the ability of Marina Biotech and/or a partner to obtain required governmental approvals; and (v) the ability of Marina Biotech and/or a partner to develop and commercialize products that can compete favorably with those of competitors. Additional factors that could cause actual results to differ materially from those projected or suggested in any forward-looking statements are contained in Marina Biotech's most recent periodic reports on Form 10-K and Form 10-Q that are filed with the Securities and Exchange Commission. Marina Biotech assumes no obligation to update and supplement forward-looking statements because of subsequent events.
Contact:
Marina Biotech, Inc.
Michael V. Templin, Ph.D.
Senior Vice President, Preclinical Development
(425) 908-3057
Email Contact
Antwort auf Beitrag Nr.: 41.763.061 von ultrawuffsn am 08.07.11 16:13:53bin long.fettes volumen.
ziel 0,60 dollar erst mal.
ziel 0,60 dollar erst mal.
Antwort auf Beitrag Nr.: 41.763.085 von ultrawuffsn am 08.07.11 16:17:43realtime!!!!!
http://www.level2stockquotes.com/level-ii-quotes.html
http://www.level2stockquotes.com/level-ii-quotes.html
Antwort auf Beitrag Nr.: 41.763.099 von ultrawuffsn am 08.07.11 16:18:570,26 ist durch.denke die geht gleich durch die decke.
Antwort auf Beitrag Nr.: 41.763.099 von ultrawuffsn am 08.07.11 16:18:57Diff. abs / Diff. rel: 0,09 EUR / 80,95%
Datum / Uhrzeit: 08.07.11 / 16:20:21
Geld / Brief: Geld: 08.07.11 - 16:22:55, Brief: 08.07.11 - 16:22:55 0,173 EUR / 0,193 EUR
die germanen legen auch los.
Datum / Uhrzeit: 08.07.11 / 16:20:21
Geld / Brief: Geld: 08.07.11 - 16:22:55, Brief: 08.07.11 - 16:22:55 0,173 EUR / 0,193 EUR
die germanen legen auch los.
Trading Spotlight
Antwort auf Beitrag Nr.: 41.763.128 von ultrawuffsn am 08.07.11 16:23:39gleich 0,30 dollar!!!!!!!geht ab die rakete.
Antwort auf Beitrag Nr.: 41.763.133 von ultrawuffsn am 08.07.11 16:25:34nächster schub über 0,30.
Antwort auf Beitrag Nr.: 41.763.168 von ultrawuffsn am 08.07.11 16:30:330,27/0,28 0,29 fetter ask.wenns dort drüber geht dann feuer frei.
Antwort auf Beitrag Nr.: 41.763.207 von ultrawuffsn am 08.07.11 16:39:04für die germanen.letzter 0,201.
Diff. abs / Diff. rel: 0,096 EUR / 91,43%
Datum / Uhrzeit: 08.07.11 / 16:36:08
Geld / Brief: Geld: 08.07.11 - 16:40:05, Brief: 08.07.11 - 16:40:05 0,180 EUR / 0,201 EUR
Diff. abs / Diff. rel: 0,096 EUR / 91,43%
Datum / Uhrzeit: 08.07.11 / 16:36:08
Geld / Brief: Geld: 08.07.11 - 16:40:05, Brief: 08.07.11 - 16:40:05 0,180 EUR / 0,201 EUR
bin auch dabei kann noch was werden
Antwort auf Beitrag Nr.: 41.763.246 von printguru am 08.07.11 16:45:19bist du es paradiso.
Antwort auf Beitrag Nr.: 41.763.246 von printguru am 08.07.11 16:45:190,28/0,29
Antwort auf Beitrag Nr.: 41.763.280 von ultrawuffsn am 08.07.11 16:50:430,60 etwas übertrieben aber 0,50 dollar könnten erst mal drinn sein.fettestes volumen heute.
Antwort auf Beitrag Nr.: 41.763.286 von ultrawuffsn am 08.07.11 16:51:58für die germanen.
Diff. abs / Diff. rel: 0,094 EUR / 89,52%
Datum / Uhrzeit: 08.07.11 / 16:44:06
Geld / Brief: Geld: 08.07.11 - 16:51:51, Brief: 08.07.11 - 16:51:51 0,187 EUR / 0,209 EUR
Diff. abs / Diff. rel: 0,094 EUR / 89,52%
Datum / Uhrzeit: 08.07.11 / 16:44:06
Geld / Brief: Geld: 08.07.11 - 16:51:51, Brief: 08.07.11 - 16:51:51 0,187 EUR / 0,209 EUR
Antwort auf Beitrag Nr.: 41.763.318 von zuzlhuba am 08.07.11 16:57:59keine ahnung mußte dich auf i-hub selber einlesen.was zählt ist das jetzt.ich sehe aufwärtstrend und fettestes volumen.da muß man dabei sein.
Antwort auf Beitrag Nr.: 41.763.332 von ultrawuffsn am 08.07.11 17:00:33die fetten ask seiten sind jetzt weg.wird vielleicht gleich losgelassen.
Antwort auf Beitrag Nr.: 41.763.361 von ultrawuffsn am 08.07.11 17:07:20Diff. abs / Diff. rel: 0,090 EUR / 85,71%
Datum / Uhrzeit: 08.07.11 / 17:11:57
Geld / Brief: Geld: 08.07.11 - 17:13:48, Brief: 08.07.11 - 17:13:48 0,185 EUR / 0,206 EUR
Datum / Uhrzeit: 08.07.11 / 17:11:57
Geld / Brief: Geld: 08.07.11 - 17:13:48, Brief: 08.07.11 - 17:13:48 0,185 EUR / 0,206 EUR
Antwort auf Beitrag Nr.: 41.763.418 von ultrawuffsn am 08.07.11 17:14:41ich muß dann bald los.werde auf alle fälle übers wochenende halten.chart sieht jetzt gut aus.1. ziel 0,50 dollar.
Antwort auf Beitrag Nr.: 41.763.440 von ultrawuffsn am 08.07.11 17:17:53Kann mal jemand einen RT-Chart reinstellen ???
...aber mit Bild...
Danke!
...aber mit Bild...
Danke!
Antwort auf Beitrag Nr.: 41.763.475 von JimmySpoon am 08.07.11 17:24:28hier ist ein RT-chart.
http://peketec.de/trading/daytrading-tradingchancen-040711-1…
http://peketec.de/trading/daytrading-tradingchancen-040711-1…
Antwort auf Beitrag Nr.: 41.763.486 von ultrawuffsn am 08.07.11 17:26:29weiter unten ist RT chart.
Antwort auf Beitrag Nr.: 41.763.492 von ultrawuffsn am 08.07.11 17:27:56seht zu das ihr das teil in den 0,30er bereich drückt dann gehts nächste woch weiter richtung 0,50.
Antwort auf Beitrag Nr.: 41.763.558 von ultrawuffsn am 08.07.11 17:40:40kannst ruhig mithelfen
aber könnte ein geiler Zock werden wenn die gegen Handelsende anziehen lege ich nocheinmal nach
Lg.Printi
denke auch die 0,5$ sind bis am Montag kurz nach Eröffnung machbar
aber könnte ein geiler Zock werden wenn die gegen Handelsende anziehen lege ich nocheinmal nach
Lg.Printi
denke auch die 0,5$ sind bis am Montag kurz nach Eröffnung machbar
wo nehmt ihr eigentlich euren optimismus her? :-)
Antwort auf Beitrag Nr.: 41.763.685 von scholi88 am 08.07.11 18:09:05den nehme ich daher daß da einige nun zocken wollen und das Teil hochtreiben werden nachbörslich
ideal wäre heute ein Schlußkurs von 0,3-0,35$ und dann nachbörslich raufgezocke bis 0,4$ und am Montag zu 0,48$ eröffnen
das würde sich dann lohnen
LG Printi
ideal wäre heute ein Schlußkurs von 0,3-0,35$ und dann nachbörslich raufgezocke bis 0,4$ und am Montag zu 0,48$ eröffnen
das würde sich dann lohnen
LG Printi
ja das stimmt!
aber ich denk eher, dass das ding nach unten gezockt wird ;-)! rein intuitiv
aber ich denk eher, dass das ding nach unten gezockt wird ;-)! rein intuitiv
Antwort auf Beitrag Nr.: 41.763.718 von scholi88 am 08.07.11 18:17:20alles möglich aber nach Oben haben wir nunmal um einiges mehr Platz als nach unten
gerade schön bei 0,26$ konsol. und jetzt wird wieder eingekauft
bin mit 100000St. dabei entweder bis Montag 20000-24000$+ oder eben per Stop bei 0,22-0,24$ raus
wie es hier weitergeht weiß wahrlich niemand aber die Amis sind nunmal Biotechzocker da weiß man nie was da noch abgeht
Lg.Printi
gerade schön bei 0,26$ konsol. und jetzt wird wieder eingekauft
bin mit 100000St. dabei entweder bis Montag 20000-24000$+ oder eben per Stop bei 0,22-0,24$ raus
wie es hier weitergeht weiß wahrlich niemand aber die Amis sind nunmal Biotechzocker da weiß man nie was da noch abgeht
Lg.Printi
jupp, die konvergiert ja schon fast gegen null. aber das haben auch einige bei crowflight (jetzt: canickel) gedacht. und es geht trotzdem noch weiter!
aber egal, is halt ne zockerposition^^!
dir auf alle fälle maximale gewinne.
aber egal, is halt ne zockerposition^^!
dir auf alle fälle maximale gewinne.
Antwort auf Beitrag Nr.: 41.763.859 von scholi88 am 08.07.11 18:46:42danke dir hat mir leider nur einen Verlust von gut 2000$ eingebracht.
aber so ist es nunmal beim Zocken
LG Printi
aber so ist es nunmal beim Zocken
LG Printi
Antwort auf Beitrag Nr.: 41.763.859 von scholi88 am 08.07.11 18:46:42danke dir hat mir leider nur einen Verlust von gut 2000$ eingebracht.
aber so ist es nunmal beim Zocken
LG Printi
aber so ist es nunmal beim Zocken
LG Printi
Antwort auf Beitrag Nr.: 41.764.670 von printguru am 08.07.11 22:57:13euch kann man auch nicht alleine lassen. ich warte mal nächste woche ab.die zocker sind raus übers wochenende.bin überzeugt das wir die 0,50 dollar anlaufen werden.
ich warte mal nächste woche ab.die zocker sind raus übers wochenende.bin überzeugt das wir die 0,50 dollar anlaufen werden. !
Dieser Beitrag wurde von MaatMod moderiert.
Antwort auf Beitrag Nr.: 41.765.071 von ultrawuffsn am 09.07.11 09:16:06--Short Volume-- 3,497,308:
))
Nextweek gonna be fun!!!
A surprise 1 Huge BlockBuy AH Friday...caught the Shorties with their pants down...lmao
na denn feuer frei.
))Nextweek gonna be fun!!!
A surprise 1 Huge BlockBuy AH Friday...caught the Shorties with their pants down...lmao
na denn feuer frei.
Antwort auf Beitrag Nr.: 41.769.758 von ultrawuffsn am 11.07.11 13:25:59RT 0,201 euronen
Antwort auf Beitrag Nr.: 41.770.068 von ultrawuffsn am 11.07.11 14:18:180,26/0,27 es geht up.
Antwort auf Beitrag Nr.: 41.770.545 von ultrawuffsn am 11.07.11 15:33:59freitag größtes volumen seit einem halben jahr über 30 mille gehandelt.
Antwort auf Beitrag Nr.: 41.770.674 von ultrawuffsn am 11.07.11 15:50:36ask ist absolut lehr.mal sehn ob das ding heute startet.
wieso sollte sie ?! ;-)
Antwort auf Beitrag Nr.: 41.770.715 von scholi88 am 11.07.11 15:56:17news von freitag lesen.
ich seh schon, die geht heut total krass ab ;-)
http://secfilings.nasdaq.com/filingFrameset.asp?FileName=000… url]" target="_blank" rel="nofollow ugc noopener"> [/http://secfilings.nasdaq.com/filingFrameset.asp?FileName=000… url]
Company News
MRNA MRNA
Marina Biotech, Inc. NASDAQ-GM
Back to Headlines | Print Version | ShareThis
Marina Biotech Announces Changes to Board of Directors
Appoints John Fletcher to Board of Directors and James Karis as Chairman
BOTHELL, WA -- (MARKET WIRE) -- 07/18/11 -- Marina Biotech, Inc. (NASDAQ: MRNA), a leading nucleic acid-based drug discovery and development company, today announced that R. John Fletcher was elected to the Company's Board of Directors effective July 14, 2011, replacing Board member Chiang Li, Ph.D., M.D., who announced his retirement from the Marina Biotech board prior to the 2011 annual meeting of shareholders. The Company also announced the appointment of James Karis, who has served as a Board member since 2009, as Chairman of the Board, effective July 14, 2011, replacing co-chairmen Gregory Sessler and Peter Parker, both of whom will continue as board members of Marina Biotech.
"I am pleased to welcome John Fletcher to Marina Biotech's Board of Directors," stated James Karis, Chairman of the Board of Directors of Marina Biotech. "John brings extensive corporate strategy and financing experience that is characterized by a strong understanding of the commercial potential of new technologies and the options for developing, funding, and acquiring new businesses. We would also like to thank Dr. Li for his service to our company and his contributions to our wholly owned subsidiary, Cequent Pharmaceuticals. In addition, I want to thank Greg and Peter for their outstanding efforts as co-Chairmen in effectively integrating the MDRNA and Cequent Boards and then leading the new Marina Biotech Board throughout this past year."
Mr. Fletcher is an independent director for purposes of the Sarbanes Oxley Act of 2002 and NASDAQ stock exchange regulations. He is a Founding Partner of Fletcher Spaght Ventures, a venture capital firm investing in emerging growth healthcare and high technology companies. He also serves as the CEO of Fletcher Spaght Inc., a management consulting firm he founded to provide strategy and financing assistance to new companies. Mr. Fletcher has over twenty-five years providing strategy and financing assistance to new companies. Prior to launching Fletcher Spaght Inc. in 1983, he served as a Senior Manager at The Boston Consulting Group, managing client relationships in healthcare and high technology companies. Mr. Fletcher attended the Wharton School of Business at the University of Pennsylvania and completed all coursework for a Ph.D. He holds an MA in International Finance from Central Michigan University, an MBA from Southern Illinois University, and a BBA from George Washington University. He is a current or past board member for many companies, including Axcelis, GlycoFi and Spectranetics.
"I'm very excited to join the board of Marina Biotech and look forward to contributing strategically to the Company as it works to develop and commercialize therapeutic products based on RNA interference," said Mr. Fletcher.
With the resignation of Dr. Li and the addition of Mr. Fletcher, there remain six members on the Marina Biotech Board of Directors.
About Marina Biotech, Inc.
Marina Biotech is a biotechnology company, focused on the development and commercialization of RNA interference- (RNAi) and RNA-based therapeutics. The Marina Biotech pipeline currently includes a clinical program in Familial Adenomatous Polyposis (a precancerous syndrome) and two preclinical programs -- in bladder cancer and malignant ascites. Marina Biotech entered into an exclusive agreement with Debiopharm Group for the development and commercialization of the bladder cancer program. Marina Biotech's goal is to improve human health through the development of RNAi- and RNA-based compounds and drug delivery technologies that together provide superior therapeutic options for patients. Additional information about Marina Biotech is available at http://www.marinabio.com.
Forward-Looking Statements
Statements made in this news release may be forward-looking statements within the meaning of Federal Securities laws that are subject to certain risks and uncertainties and involve factors that may cause actual results to differ materially from those projected or suggested. Factors that could cause actual results to differ materially from those in forward-looking statements include, but are not limited to: (i) the ability of Marina Biotech to obtain additional funding; (ii) the ability of Marina Biotech to attract and/or maintain manufacturing, research, development and commercialization partners; (iii) the ability of Marina Biotech and/or a partner to successfully complete product research and development, including preclinical and clinical studies and commercialization; (iv) the ability of Marina Biotech and/or a partner to obtain required governmental approvals; and (v) the ability of Marina Biotech and/or a partner to develop and commercialize products that can compete favorably with those of competitors. Additional factors that could cause actual results to differ materially from those projected or suggested in any forward-looking statements are contained in Marina Biotech's most recent periodic reports on Form 10-K and Form 10-Q that are filed with the Securities and Exchange Commission. Marina Biotech assumes no obligation to update and supplement forward-looking statements because of subsequent events.
Contact:
Marina Biotech, Inc.Peter Garcia
Chief Financial Officer
(425) 908-3603
Email Contact
Source: Marina Biotech, Inc.
Latest "In Focus" News Stories
Haven commodities boosted by concerns over debt
Jul 18, 2011
Google and Facebook - why the search giant needs social networks
Jul 16, 2011
US close to sovereign ratings cut
Jul 14, 2011
How far is too far for News Corp?
Jul 7, 2011
Decline and fall of the Greek credit rating
Jul 5, 2011
Read more: http://www.nasdaq.com/aspx/company-news-story.aspx?storyid=2…
MRNA MRNA
Marina Biotech, Inc. NASDAQ-GM
Back to Headlines | Print Version | ShareThis
Marina Biotech Announces Changes to Board of Directors
Appoints John Fletcher to Board of Directors and James Karis as Chairman
BOTHELL, WA -- (MARKET WIRE) -- 07/18/11 -- Marina Biotech, Inc. (NASDAQ: MRNA), a leading nucleic acid-based drug discovery and development company, today announced that R. John Fletcher was elected to the Company's Board of Directors effective July 14, 2011, replacing Board member Chiang Li, Ph.D., M.D., who announced his retirement from the Marina Biotech board prior to the 2011 annual meeting of shareholders. The Company also announced the appointment of James Karis, who has served as a Board member since 2009, as Chairman of the Board, effective July 14, 2011, replacing co-chairmen Gregory Sessler and Peter Parker, both of whom will continue as board members of Marina Biotech.
"I am pleased to welcome John Fletcher to Marina Biotech's Board of Directors," stated James Karis, Chairman of the Board of Directors of Marina Biotech. "John brings extensive corporate strategy and financing experience that is characterized by a strong understanding of the commercial potential of new technologies and the options for developing, funding, and acquiring new businesses. We would also like to thank Dr. Li for his service to our company and his contributions to our wholly owned subsidiary, Cequent Pharmaceuticals. In addition, I want to thank Greg and Peter for their outstanding efforts as co-Chairmen in effectively integrating the MDRNA and Cequent Boards and then leading the new Marina Biotech Board throughout this past year."
Mr. Fletcher is an independent director for purposes of the Sarbanes Oxley Act of 2002 and NASDAQ stock exchange regulations. He is a Founding Partner of Fletcher Spaght Ventures, a venture capital firm investing in emerging growth healthcare and high technology companies. He also serves as the CEO of Fletcher Spaght Inc., a management consulting firm he founded to provide strategy and financing assistance to new companies. Mr. Fletcher has over twenty-five years providing strategy and financing assistance to new companies. Prior to launching Fletcher Spaght Inc. in 1983, he served as a Senior Manager at The Boston Consulting Group, managing client relationships in healthcare and high technology companies. Mr. Fletcher attended the Wharton School of Business at the University of Pennsylvania and completed all coursework for a Ph.D. He holds an MA in International Finance from Central Michigan University, an MBA from Southern Illinois University, and a BBA from George Washington University. He is a current or past board member for many companies, including Axcelis, GlycoFi and Spectranetics.
"I'm very excited to join the board of Marina Biotech and look forward to contributing strategically to the Company as it works to develop and commercialize therapeutic products based on RNA interference," said Mr. Fletcher.
With the resignation of Dr. Li and the addition of Mr. Fletcher, there remain six members on the Marina Biotech Board of Directors.
About Marina Biotech, Inc.
Marina Biotech is a biotechnology company, focused on the development and commercialization of RNA interference- (RNAi) and RNA-based therapeutics. The Marina Biotech pipeline currently includes a clinical program in Familial Adenomatous Polyposis (a precancerous syndrome) and two preclinical programs -- in bladder cancer and malignant ascites. Marina Biotech entered into an exclusive agreement with Debiopharm Group for the development and commercialization of the bladder cancer program. Marina Biotech's goal is to improve human health through the development of RNAi- and RNA-based compounds and drug delivery technologies that together provide superior therapeutic options for patients. Additional information about Marina Biotech is available at http://www.marinabio.com.
Forward-Looking Statements
Statements made in this news release may be forward-looking statements within the meaning of Federal Securities laws that are subject to certain risks and uncertainties and involve factors that may cause actual results to differ materially from those projected or suggested. Factors that could cause actual results to differ materially from those in forward-looking statements include, but are not limited to: (i) the ability of Marina Biotech to obtain additional funding; (ii) the ability of Marina Biotech to attract and/or maintain manufacturing, research, development and commercialization partners; (iii) the ability of Marina Biotech and/or a partner to successfully complete product research and development, including preclinical and clinical studies and commercialization; (iv) the ability of Marina Biotech and/or a partner to obtain required governmental approvals; and (v) the ability of Marina Biotech and/or a partner to develop and commercialize products that can compete favorably with those of competitors. Additional factors that could cause actual results to differ materially from those projected or suggested in any forward-looking statements are contained in Marina Biotech's most recent periodic reports on Form 10-K and Form 10-Q that are filed with the Securities and Exchange Commission. Marina Biotech assumes no obligation to update and supplement forward-looking statements because of subsequent events.
Contact:
Marina Biotech, Inc.Peter Garcia
Chief Financial Officer
(425) 908-3603
Email Contact
Source: Marina Biotech, Inc.
Latest "In Focus" News Stories
Haven commodities boosted by concerns over debt
Jul 18, 2011
Google and Facebook - why the search giant needs social networks
Jul 16, 2011
US close to sovereign ratings cut
Jul 14, 2011
How far is too far for News Corp?
Jul 7, 2011
Decline and fall of the Greek credit rating
Jul 5, 2011
Read more: http://www.nasdaq.com/aspx/company-news-story.aspx?storyid=2…
Marina Biotech, Inc.
(NasdaqGM: MRNA )
Real Time 0.2260 Up 0.0210 (10.24%) 1:26PM EDT
Stand: 21. 07. 2011MARINA BIOTECH INC. REGISTERED SHARES DL -,006
WKN: A1C2PQ ISIN: US56804Q1022 Branche: Biotechnologie Land: USA
Times & Sales
Uhrzeit Kurs letztes Volumen kumuliert
20:20:28 0,247 100 4.036.346
20:20:28 0,247 500 4.036.246
20:20:28 0,247 100 4.035.746
20:20:28 0,247 100 4.035.646
20:20:27 0,247 400 4.035.546
20:20:27 0,247 100 4.035.146
20:20:27 0,247 100 4.035.046
20:20:26 0,247 100 4.034.946
20:20:25 0,247 2.900 4.034.846
20:20:25 0,247 100 4.031.946
20:20:25 0,247 100 4.031.846
20:20:24 0,247 100 4.031.746
20:20:23 0,247 100 4.031.646
20:20:23 0,247 3.600 4.031.546
20:20:22 0,247 3.600 4.027.946
20:19:54 0,249 50.000 4.024.346
20:19:54 0,249 3.600 3.974.346
20:19:54 0,249 77.134 3.970.746
das sind aber ein paar fette Käufe in USA
WKN: A1C2PQ ISIN: US56804Q1022 Branche: Biotechnologie Land: USA
Times & Sales
Uhrzeit Kurs letztes Volumen kumuliert
20:20:28 0,247 100 4.036.346
20:20:28 0,247 500 4.036.246
20:20:28 0,247 100 4.035.746
20:20:28 0,247 100 4.035.646
20:20:27 0,247 400 4.035.546
20:20:27 0,247 100 4.035.146
20:20:27 0,247 100 4.035.046
20:20:26 0,247 100 4.034.946
20:20:25 0,247 2.900 4.034.846
20:20:25 0,247 100 4.031.946
20:20:25 0,247 100 4.031.846
20:20:24 0,247 100 4.031.746
20:20:23 0,247 100 4.031.646
20:20:23 0,247 3.600 4.031.546
20:20:22 0,247 3.600 4.027.946
20:19:54 0,249 50.000 4.024.346
20:19:54 0,249 3.600 3.974.346
20:19:54 0,249 77.134 3.970.746
das sind aber ein paar fette Käufe in USA
sehr guter SK Na hoffentlich können wir das morgen halten
----------
7/21/2011 Market Closed
MRNA's NASDAQ Last Sale
0.266 0.061 29.75%
NLS Volume
2,906,527 Previous Close
$ 0.205
Today's High
$ 0.2660 Today's Low
$ 0.1919
52 Wk High
$ 3.49 52 Wk Low
$ .1433
Na hoffentlich können wir das morgen halten----------
7/21/2011 Market Closed
MRNA's NASDAQ Last Sale
0.266 0.061 29.75%
NLS Volume
2,906,527 Previous Close
$ 0.205
Today's High
$ 0.2660 Today's Low
$ 0.1919
52 Wk High
$ 3.49 52 Wk Low
$ .1433
sieht ja vorbörslich richtig gut aus
Marina Biotech Demonstrates In Vivo Dose-Dependent Efficacy and High Tolerability With a CRN-Substituted miRNA Antagonist
19 Oct 2011
A microRNA (miRNA) Antagonist Substituted With Marina Biotech's Proprietary Conformationally Restricted Nucleotides (CRN) Produced Dose-Dependent, In Vivo De-Repression of Multiple Downstream Target Genes and Was Well Tolerated at up to 50 mg/kg Daily for Three Consecutive Days
BOTHELL, WA, USA | October 19, 2011 | Marina Biotech, Inc. (NASDAQ: MRNA), a leading oligonucleotide-based drug discovery and development company, reported in vivo dose-dependent efficacy with a CRN-substituted miRNA antagonist, or antagomir, against microRNA-122 (miR-122). The efficacy in a rodent model was demonstrated by up to a 5-fold increase in AldoA, a well-known downstream gene regulated by miR-122. Downstream targets Glycogen Synthase I (GYS1) and Solute Carrier Family 7 member 1 (SLC7A1) were also elevated. The increase in these downstream gene targets was achieved by the sequestration of miR-122 by a high affinity CRN-substituted antagomir. In addition, the CRN-substituted antagomir, which was dosed for three consecutive days at up to 50 mg/kg/day, was extremely well tolerated in rodents as evidenced by normal serum chemistry parameters and no body weight changes.
"Dose-dependent and robust efficacy and tolerability at high doses are significant achievements in the development of both our CRN technology as well as our broad oligonucleotide-based drug discovery platform," stated Richard T. Ho, M.D.-Ph.D, Executive Vice President, Research and Development at Marina Biotech. "Establishing proof-of-concept data enables us to use CRN technology for both single-stranded and double-stranded oligonucleotide-based therapeutic applications. This work also demonstrates that our proprietary CRN technology is well tolerated in a repeat dose regimen at high doses in a rodent model."
MicroRNAs are a novel class of small non-coding RNAs that have been shown to regulate gene expression at the post-transcriptional level by binding to their target genes. The vast number of complex gene networks tightly regulated by microRNA includes cell growth, differentiation, and apoptosis. Low expression or overexpression of specific microRNAs can lead to abnormal expression of downstream target messenger RNAs causing physiological changes associated with certain disease pathologies. Inhibition of an aberrant microRNA with an antagonist, or supplementation with a microRNA mimetic, are novel approaches to develop much needed therapeutic modalities for cancers and other diseases.
About Conformationally Restricted Nucleotides.
Conformationally Restricted Nucleotides are analogs in which a chemical bridge connects the C2' and C4' carbons of ribose. Ribose, a five-carbon ring-like structure, forms the central region of a nucleotide (comprised of a nucleobase, ribose, and phosphate group). The chemical bridge in the ribose of a CRN locks the ribose in a fixed position, which in turn restricts the flexibility of the nucleobase and phosphate group. Substitution of a CRN within an RNA- or DNA-based oligonucleotide has the advantages of increased hybridization affinity and enhanced resistance to nuclease degradation. CRN technology provides a direct means of developing highly potent and specific oligonucleotide-based therapeutics to target messenger RNAs or microRNAs. These targets connect disease pathways that are typically "undruggable" or "difficult to target" with small molecules or monoclonal antibodies, and may be critical in disease areas with significant unmet needs, such as inflammation, metabolic disease, and cancers. Marina Biotech's CRN patent estate consists of two issued patents broadly covering CRN compounds and CRN containing oligonucleotides, and one pending patent application covering additional applications of CRNs.
About Marina Biotech, Inc.
Marina Biotech is a biotechnology company, focused on the development and commercialization of oligonucleotide-based therapeutics utilizing multiple mechanisms of action including RNA interference (RNAi) and messenger RNA translational blocking. The Marina Biotech pipeline currently includes a clinical program in Familial Adenomatous Polyposis (a precancerous syndrome) and two preclinical programs -- in bladder cancer and malignant ascites. Marina Biotech entered into an exclusive agreement with Debiopharm Group for the development and commercialization of the bladder cancer program. Marina Biotech's goal is to improve human health through the development of RNAi- and oligonucleotide-based compounds and drug delivery technologies that together provide superior therapeutic options for patients. Additional information about Marina Biotech is available at http://www.marinabio.com.
SOURCE: Marina Biotech, Inc.
19 Oct 2011
A microRNA (miRNA) Antagonist Substituted With Marina Biotech's Proprietary Conformationally Restricted Nucleotides (CRN) Produced Dose-Dependent, In Vivo De-Repression of Multiple Downstream Target Genes and Was Well Tolerated at up to 50 mg/kg Daily for Three Consecutive Days
BOTHELL, WA, USA | October 19, 2011 | Marina Biotech, Inc. (NASDAQ: MRNA), a leading oligonucleotide-based drug discovery and development company, reported in vivo dose-dependent efficacy with a CRN-substituted miRNA antagonist, or antagomir, against microRNA-122 (miR-122). The efficacy in a rodent model was demonstrated by up to a 5-fold increase in AldoA, a well-known downstream gene regulated by miR-122. Downstream targets Glycogen Synthase I (GYS1) and Solute Carrier Family 7 member 1 (SLC7A1) were also elevated. The increase in these downstream gene targets was achieved by the sequestration of miR-122 by a high affinity CRN-substituted antagomir. In addition, the CRN-substituted antagomir, which was dosed for three consecutive days at up to 50 mg/kg/day, was extremely well tolerated in rodents as evidenced by normal serum chemistry parameters and no body weight changes.
"Dose-dependent and robust efficacy and tolerability at high doses are significant achievements in the development of both our CRN technology as well as our broad oligonucleotide-based drug discovery platform," stated Richard T. Ho, M.D.-Ph.D, Executive Vice President, Research and Development at Marina Biotech. "Establishing proof-of-concept data enables us to use CRN technology for both single-stranded and double-stranded oligonucleotide-based therapeutic applications. This work also demonstrates that our proprietary CRN technology is well tolerated in a repeat dose regimen at high doses in a rodent model."
MicroRNAs are a novel class of small non-coding RNAs that have been shown to regulate gene expression at the post-transcriptional level by binding to their target genes. The vast number of complex gene networks tightly regulated by microRNA includes cell growth, differentiation, and apoptosis. Low expression or overexpression of specific microRNAs can lead to abnormal expression of downstream target messenger RNAs causing physiological changes associated with certain disease pathologies. Inhibition of an aberrant microRNA with an antagonist, or supplementation with a microRNA mimetic, are novel approaches to develop much needed therapeutic modalities for cancers and other diseases.
About Conformationally Restricted Nucleotides.
Conformationally Restricted Nucleotides are analogs in which a chemical bridge connects the C2' and C4' carbons of ribose. Ribose, a five-carbon ring-like structure, forms the central region of a nucleotide (comprised of a nucleobase, ribose, and phosphate group). The chemical bridge in the ribose of a CRN locks the ribose in a fixed position, which in turn restricts the flexibility of the nucleobase and phosphate group. Substitution of a CRN within an RNA- or DNA-based oligonucleotide has the advantages of increased hybridization affinity and enhanced resistance to nuclease degradation. CRN technology provides a direct means of developing highly potent and specific oligonucleotide-based therapeutics to target messenger RNAs or microRNAs. These targets connect disease pathways that are typically "undruggable" or "difficult to target" with small molecules or monoclonal antibodies, and may be critical in disease areas with significant unmet needs, such as inflammation, metabolic disease, and cancers. Marina Biotech's CRN patent estate consists of two issued patents broadly covering CRN compounds and CRN containing oligonucleotides, and one pending patent application covering additional applications of CRNs.
About Marina Biotech, Inc.
Marina Biotech is a biotechnology company, focused on the development and commercialization of oligonucleotide-based therapeutics utilizing multiple mechanisms of action including RNA interference (RNAi) and messenger RNA translational blocking. The Marina Biotech pipeline currently includes a clinical program in Familial Adenomatous Polyposis (a precancerous syndrome) and two preclinical programs -- in bladder cancer and malignant ascites. Marina Biotech entered into an exclusive agreement with Debiopharm Group for the development and commercialization of the bladder cancer program. Marina Biotech's goal is to improve human health through the development of RNAi- and oligonucleotide-based compounds and drug delivery technologies that together provide superior therapeutic options for patients. Additional information about Marina Biotech is available at http://www.marinabio.com.
SOURCE: Marina Biotech, Inc.
Marina Biotech Demonstrates That Its Novel UsiRNA Oligonucleotide Abrogates Cytotoxicity Resulting From microRNA-Like Off-Target Activity
02 Nov 2011
Data Generated Under an Early Collaborative Effort Demonstrated Abrogation of Cytotoxicity Associated With microRNA-Like Off-Targeting by Substituting a Single Unlocked Nucleobase Analog (UNA) Moiety in the Guide Strand of an siRNA (UsiRNA)
BOTHELL, WA, USA I November 2, 2011 I Marina Biotech, Inc. (NASDAQ: MRNA - News), a leading oligonucleotide-based drug discovery and development company, reported significant reduction of microRNA-like cytotoxic effect by incorporating a single UNA moiety in the guide strand of an siRNA when compared to an unmodified siRNA of the same sequence. The data was generated under one of the Company's early collaborative efforts. Unmodified siRNAs can induce unintended effects, including cytotoxicity, which can lead to safety issues. Substitution with a single UNA in the seed region of the siRNA guide strand resulted in abrogation of cell death/anti-proliferation effects associated with a specific siRNA preclinical candidate for which unintended microRNA targets had already been identified.
"These results further confirm the utility and breadth of our UNA technology in mitigating an undesirable effect associated with unmodified siRNAs," stated Richard T. Ho, M.D.-Ph.D., Executive Vice President, Research and Development at Marina Biotech, Inc. "This work confirms our experience that the majority of unintended microRNA related off-target events are likely to be reduced by placing a UNA in the seed region of the siRNA guide strand. The ability to "rescue" a highly active siRNA by dramatically reducing its cytotoxic effects with a single UNA substitution emphasizes the advantages of the UNA technology and the UsiRNA platform in the development of oligonucleotide therapeutics which capitalize on the power of the RNAi pathway."
UNA are non-nucleotide, acyclic monomers which provide greater structural flexibility in an oligonucleotide strand. Marina Biotech's proprietary UsiRNA constructs are siRNA incorporating at least one UNA and are distinct from the standard siRNA constructs used by others in the industry. UsiRNAs are specifically designed to provide greater specificity for RNAi-based therapeutics. Substitution with UNA in the passenger strand (non-targeting strand) is intended to eliminate its participation in the RNAi process. Substitution in the guide strand (targeting strand) is intended to eliminate miRNA-like events, while preserving high siRNA-like activity. Optimization of UNA substitutions in siRNA has previously been published by Marina Biotech (Nucleic Acids Res. 2011 Mar;39(5):1823-32.).
SOURCE: Marina Biotech
02 Nov 2011
Data Generated Under an Early Collaborative Effort Demonstrated Abrogation of Cytotoxicity Associated With microRNA-Like Off-Targeting by Substituting a Single Unlocked Nucleobase Analog (UNA) Moiety in the Guide Strand of an siRNA (UsiRNA)
BOTHELL, WA, USA I November 2, 2011 I Marina Biotech, Inc. (NASDAQ: MRNA - News), a leading oligonucleotide-based drug discovery and development company, reported significant reduction of microRNA-like cytotoxic effect by incorporating a single UNA moiety in the guide strand of an siRNA when compared to an unmodified siRNA of the same sequence. The data was generated under one of the Company's early collaborative efforts. Unmodified siRNAs can induce unintended effects, including cytotoxicity, which can lead to safety issues. Substitution with a single UNA in the seed region of the siRNA guide strand resulted in abrogation of cell death/anti-proliferation effects associated with a specific siRNA preclinical candidate for which unintended microRNA targets had already been identified.
"These results further confirm the utility and breadth of our UNA technology in mitigating an undesirable effect associated with unmodified siRNAs," stated Richard T. Ho, M.D.-Ph.D., Executive Vice President, Research and Development at Marina Biotech, Inc. "This work confirms our experience that the majority of unintended microRNA related off-target events are likely to be reduced by placing a UNA in the seed region of the siRNA guide strand. The ability to "rescue" a highly active siRNA by dramatically reducing its cytotoxic effects with a single UNA substitution emphasizes the advantages of the UNA technology and the UsiRNA platform in the development of oligonucleotide therapeutics which capitalize on the power of the RNAi pathway."
UNA are non-nucleotide, acyclic monomers which provide greater structural flexibility in an oligonucleotide strand. Marina Biotech's proprietary UsiRNA constructs are siRNA incorporating at least one UNA and are distinct from the standard siRNA constructs used by others in the industry. UsiRNAs are specifically designed to provide greater specificity for RNAi-based therapeutics. Substitution with UNA in the passenger strand (non-targeting strand) is intended to eliminate its participation in the RNAi process. Substitution in the guide strand (targeting strand) is intended to eliminate miRNA-like events, while preserving high siRNA-like activity. Optimization of UNA substitutions in siRNA has previously been published by Marina Biotech (Nucleic Acids Res. 2011 Mar;39(5):1823-32.).
SOURCE: Marina Biotech
Marina Biotech receives Chinese patent for Insulin Delivery Formulations
18 November 2011
Marina Biotech has received patent rights from the State Intellectual Property Office of the People's Republic of China (PRC) for its intranasal delivery of insulin.
The formulation is used to treat diseases associated with inappropriate insulin levels.
Preclinical studies including Phase 1 and multicenter Phase 2 clinical trials have proven the efficacy of the formulation.
Insulin is delivered to the nasal mucosa and does not enter the lungs.
The move is believed to strengthen the insulin patent portfolio in China.
18 November 2011
Marina Biotech has received patent rights from the State Intellectual Property Office of the People's Republic of China (PRC) for its intranasal delivery of insulin.
The formulation is used to treat diseases associated with inappropriate insulin levels.
Preclinical studies including Phase 1 and multicenter Phase 2 clinical trials have proven the efficacy of the formulation.
Insulin is delivered to the nasal mucosa and does not enter the lungs.
The move is believed to strengthen the insulin patent portfolio in China.
DurchsuchenBeitrag zu dieser Diskussion schreiben
Zu dieser Diskussion können keine Beiträge mehr verfasst werden, da der letzte Beitrag vor mehr als zwei Jahren verfasst wurde und die Diskussion daraufhin archiviert wurde.
Bitte wenden Sie sich an feedback@wallstreet-online.de und erfragen Sie die Reaktivierung der Diskussion oder starten Sie eine neue Diskussion.
Investoren beobachten auch:
| Wertpapier | Perf. % |
|---|---|
| +1,35 | |
| -0,31 | |
| -6,82 | |
| -0,11 | |
| -0,30 | |
| 0,00 | |
| -3,86 | |
| -1,79 | |
| +1,27 | |
| - |
Meistdiskutiert
| Wertpapier | Beiträge | |
|---|---|---|
| 203 | ||
| 190 | ||
| 147 | ||
| 69 | ||
| 31 | ||
| 29 | ||
| 29 | ||
| 25 | ||
| 25 | ||
| 25 |
